Kits for Converting Nanocrystals to Standard Bio-Medical Reagents
Kits for Converting Nanocrystals to Standard Bio-Medical Reagents
批准号:
7498032
负责人:
DAVID Mark BATTAGLIA
金额:
$40.2万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-05 至 2009-08-31
关键词:
AddressArkansasAwardBenignBio-BaseBiochemistryBuffersBusinessesCadmiumChemistryConditionConsultCoupledDetectionDiagnosticDyesElementsEquilibriumEuropean UnionFluorescenceFluorescence Resonance Energy TransferGenerationsHeavy MetalsIndustryIonsJointsLabelLegal patentLifeLigandsMarketingMedicalMissionOrangesPermeabilityPhasePhysiologyPositioning AttributeProteinsQuantum DotsRangeRare Earth MetalsReagentRightsRuralScienceScientistSemiconductorsSmall Business Funding MechanismsSmall Business Innovation Research GrantStandards of Weights and MeasuresTechnologyTemperatureTransition ElementsUnited StatesUnited States National Institutes of HealthUniversitiesZincbasecadmium selenideexperienceknowledge basemedical schoolsnanocrystalnanometerprofessorprogramsquantumresearch and developmentsizeskillssuccess
中文摘要
描述(由申请人提供):SBIR二期项目旨在开发第二代基于半导体纳米晶体(q点)的生物医学标签,以消除有毒镉元素的使用,具有物理渗透性,并且不具有任何自猝灭的光致发光。这将通过一项新发明来实现,即基于掺杂非镉半导体纳米晶体(d-dots)的亮纳米晶体发射器,以及在第一阶段开发的树突纳米晶体技术。NN-Labs拥有这两项关键技术的独家专利权。为了完成这个二期项目,我们组建了一个技术和商业上平衡的团队,其中原始发明者、NN-Labs的科学家和阿肯萨斯大学彭小刚教授的团队(分包商)作为研发团队,斯坦福医学院的Shawn Chen教授作为医疗合作伙伴,Sigma-Aldrich作为营销合作伙伴,ImmunoVision (IVAX诊断公司在阿肯萨斯的子公司)作为战略合作伙伴。与传统荧光标记相比,d点标记几乎具有q点标记的所有优点。q点标签目前在世界范围内用于诊断和其他类型的生物医学检测。然而,主力军硒化镉和相关q点是有问题的。例如,欧盟将在今年夏天开始禁止任何含有故意添加的新产品。这一重大挑战将由d点技术很好地解决,该技术依赖于锌基半导体纳米晶体中掺杂中心的可调谐发射。这种独特的荧光机制使得d点具有零自猝灭和热稳定性,这是有机染料和q点标签的固有问题。独特的发射机制和树突-纳米晶体技术将d点标签的总尺寸减小到典型蛋白质的大小(几纳米),大大小于目前标准产品的q点标签,尺寸为几十纳米。虽然q点技术目前被世界各地的公司所追求,但NN-Labs在d点树突纳米晶体方面的独特专利地位可能会使美国在这个有前途的行业领域领先于其他竞争对手。阿肯色州需要这样的机会来实现其长期使命,将这个传统的农村州发展成为一个以知识为基础的、环境友好的工业港口。
英文摘要
DESCRIPTION (provided by applicant): This SBIR Phase II program intends to develop the second generation of semiconductor nanocrystals (q-dots) based bio-medical labels to eliminate the usage of toxic cadmium element, to be physically permeable, and to not possess any self-quenching of the photoluminescence. This will be realized by a new invention, bright nanocrystal emitters based on doped non- cadmium semiconductor nanocrystals (d-dots), and the dendron-nanocrystal technology developed in the Phase I. NN-Labs has the exclusive patent rights for both key technologies. To accomplish this Phase II program, a balanced team in technology and business is assembled, with the original inventors, the scientists at NN-Labs and Professor Xiaogang Peng's group at the University of Arkansas (subcontractor), as the R&D team, Professor Shawn Chen at Stanford School of Medicine as the Medical Partner, Sigma-Aldrich as the Marketing Partner, and ImmunoVision (a subsidiary at Arkansas of IVAX diagnostics) as the Strategic Partner. D-dot labels possess nearly all advantages of q-dot labels in comparison to traditional fluorescent labels. Q-dot labels are currently developed for diagnostics and other types of bio- medical detection worldwide. However, the workhorse, cadmium selenide and related q-dots, is problematic. For example, European Union will start to ban any new products containing intentionally added in this summer. This major challenge will be nicely solved by d-dots technology, which relies on tunable emissions of doping centers in zinc based semiconductor nanocrystals. This unique fluorescence mechanism makes d-dots have zero self-quenching and thermally stable, which is an intrinsic problem for both organic dyes and q-dot labels. The unique emission mechanism and the dendron-nanocrystal technology reduce the total size of d- dot labels to that of a typical protein (a few nanometers), which is substantially smaller than the current standard products of q-dots labels, several tens of nanometers in size. Although q-dot technologies are currently pursued by companies worldwide, the unique patent position of NN-Labs on d-dot dendron-nanocrystals will likely place United States in front of other competitors in this promising industry field. Such opportunities are needed for the State of Arkansas to meet its long term mission, to develop this traditionally rural state to a knowledge- based and environmentally benign industry harbor.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Self-Detoxifying Filter Media for Active Decontamination
-
批准号:10155952
-
项目类别:
-
资助金额:$25.08万
-
财政年份:2020
-
负责人:DAVID Mark BATTAGLIA
-
依托单位:
Enhanced Non fouling Membranes for Water Purification and Recycling
-
批准号:8779813
-
项目类别:
-
资助金额:$22.45万
-
财政年份:2014
-
负责人:DAVID Mark BATTAGLIA
-
依托单位:
Enhanced Non Fouling Membranes for Water Purification and Recycling
-
批准号:9355646
-
项目类别:
-
资助金额:$40.27万
-
财政年份:2014
-
负责人:DAVID Mark BATTAGLIA
-
依托单位:
High Yield and Inexpensive Production of Quality Gold Nanocrystals for Bio-Labels
-
批准号:7052658
-
项目类别:
-
资助金额:$9.85万
-
财政年份:2006
-
负责人:DAVID Mark BATTAGLIA
-
依托单位:
MATERNAL AGING AND MEIOTIC REGULATION IN OOCYTES
-
批准号:2204737
-
项目类别:
-
资助金额:$17.89万
-
财政年份:1994
-
负责人:DAVID Mark BATTAGLIA
-
依托单位:
MATERNAL AGING AND MEIOTIC REGULATION IN OOCYTES
-
批准号:2204738
-
项目类别:
-
资助金额:$18.49万
-
财政年份:1994
-
负责人:DAVID Mark BATTAGLIA
-
依托单位:
MATERNAL AGING AND MEIOTIC REGULATION IN OOCYTES
-
批准号:2673768
-
项目类别:
-
资助金额:$18.43万
-
财政年份:1994
-
负责人:DAVID Mark BATTAGLIA
-
依托单位:
MATERNAL AGING AND MEIOTIC REGULATION IN OOCYTES
-
批准号:2204736
-
项目类别:
-
资助金额:$19.21万
-
财政年份:1994
-
负责人:DAVID Mark BATTAGLIA
-
依托单位:
MATERNAL AGING AND MEIOTIC REPRODUCTION IN OOCYTES
-
批准号:2889117
-
项目类别:
-
资助金额:$19.0万
-
财政年份:1994
-
负责人:DAVID Mark BATTAGLIA
-
依托单位:
MATERNAL AGING AND MEIOTIC REPRODUCTION IN OOCYTES
-
批准号:2389521
-
项目类别:
-
资助金额:$18.19万
-
财政年份:1994
-
负责人:DAVID Mark BATTAGLIA
-
依托单位:
IDENTIFICATION OF A SPECIFIC VITELLINE LAYER RECEPTOR
-
批准号:3048375
-
项目类别:
-
资助金额:$1.9万
-
财政年份:1987
-
负责人:DAVID Mark BATTAGLIA
-
依托单位:
IDENTIFICATION OF A SPECIFIC VITELLINE LAYER RECEPTOR
-
批准号:3048376
-
项目类别:
-
资助金额:$2.0万
-
财政年份:1987
-
负责人:DAVID Mark BATTAGLIA
-
依托单位:
海外基金